TY - JOUR T1 - Effectiveness of footwear and foot orthoses for calcaneal apophysitis: a 12-month factorial randomised trial JF - British Journal of Sports Medicine JO - Br J Sports Med SP - 1268 LP - 1275 DO - 10.1136/bjsports-2015-094986 VL - 50 IS - 20 AU - Alicia M James AU - Cylie M Williams AU - Terry P Haines Y1 - 2016/10/01 UR - http://bjsm.bmj.com/content/50/20/1268.abstract N2 - Objective Calcaneal apophysitis, is a relatively common cause of heel pain in children. Very few randomised studies have evaluated treatment options. This trial compared the effectiveness of currently employed treatment options for the relief of pain and disability associated with calcaneal apophysitis.Design Factorial 2×2 randomised comparative effectiveness trial with 1, 2, 6 and 12-month follow-up.Setting Participants were recruited from the caseload of podiatrists at Monash health and Peninsula Health.Participants Children aged 8–14 years with clinically diagnosed calcaneal apophysitis.Interventions Treatment factor 1: two different types of in-shoe orthoses: a heel raise or prefabricated orthoses. Treatment factor 2: footwear replacement or no footwear replacement.Outcomes Our primary outcome was functional disability, the secondary outcomes were pain and ankle dorsiflexion range.Results A total of 133 children and their parents responded to the recruitment advertisement, 124 participated in the trial.At the 1 and 2-month follow-up points, there was a main effect of the shoe insert (heel raise) in only the physical domain for the Oxford ankle foot questionnaire (p=0.04). At the 6 and 12-month follow-up points, there was no main effect or interaction effect for any outcome measure.Conclusion This trial indicates at the 2-month time point there is a relative advantage in the use of heel raises over prefabricated orthoses for the treatment for calcaneal apophysitis. At 12 months there was no relative advantage to any one of the investigated treatment choices over another. Therefore, if a physical impact is experienced for greater than 2 months, the selection of treatment choice may defer to clinical judgement, cost-minimisation and or patient preference.Trial registration number ACTRN12609000696291. ER -